NCT02273557View on ClinicalTrials.gov

Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

February 28, 2003

Conditions
Healthy
Interventions
DRUG

Asasantin ER (new formulation I - low)

DRUG

Asasantin ER (new formulation III - medium)

DRUG

Asasantin ER (new formulation II - high)

DRUG

Asasantin ER (present commercial formulation)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02273557 - Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects | Biotech Hunter | Biotech Hunter